All In Biotech

Drug Trial Radar · NCT06116240

A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors

A Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

135

Planned (sponsor's estimate)

Start

Sep 2, 2022

Primary completion

Dec 2023

Study completion Dec 2023

Sponsor

Sponsor type
Industry
First posted
Nov 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib clinical trial to evaluate the safety and efficacy of TQB2450 injection combined with AL2846 capsules in patients with advanced solid tumors.

Conditions

  • Solid Tumor

Interventions

  • TQB2450 injectionDrug

    TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).

  • AL2846 capsuleDrug

    AL2846 is a multi-targeted tyrosine kinase receptor inhibitor

  • Pemetrexed disodium for injectionDrug

    Pemetrexed disodium is a multi-target antifolate antineoplastic drug.

  • Cisplatin injectionDrug

    Cisplatin is a chemotherapy drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: Baseline up to 96 weeks

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Jiangmen Central Hospital

    Jiangmen, Guangdong, China

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • Inner Mongolia Baotou Steel Hospital

    Baotou, Neimenggu, China

  • Shandong First Medical University Affiliated Cancer Hospital

    Jinan, Shandong, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China

  • The Second Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, China

  • Tianjin Chest Hospital

    Tianjin, Tianjin Municipality, China

  • Tianjin Fifth Central Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.